FIG. 4.
A single 4-week course of PMPA treatment initiated on day 5 postinfection prevented irreversible CD4+ T-cell depletion and durably controlled virus replication in three of four treated animals. Four rhesus monkeys (N056, N077, BC74, and BI36) were inoculated intravenously with 103 TCID50 of the SHIVDH12R stock and treated for 4 weeks with PMPA (30 mg administered intramuscularly per day/kg of body weight) beginning on day 5 postinfection. An untreated monkey (5981) was inoculated intravenously with 650 TCID50 of SHIVDH12R. The insets in each panel highlight percent CD4+ T-lymphocyte (upper panel) and the plasma viral RNA (lower panel) levels during the initial 25 weeks of infection. The stippled bar in each inset indicates the 4-week period of PMPA administration.